Edesa Biotech Inc EDSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.94
- Day Range
- $4.79–5.52
- 52-Week Range
- $0.72–20.32
- Bid/Ask
- $4.90 / $5.35
- Shares Outstanding
- 8.89M
- Market Cap
- $46.33M
- Volume/Avg
- 149,934 / 915,205
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.edesabiotech.com
Valuation
|
Metric
|
EDSA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 24.41 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
EDSA
Financial Strength
|
Metric
|
EDSA
|
|---|---|
Quick Ratio | 4.67 |
Current Ratio | 4.76 |
Interest Coverage | — |
Quick Ratio
EDSA
Profitability
|
Metric
|
EDSA
|
|---|---|
Return on Assets (Normalized) | −63.97% |
Return on Equity (Normalized) | −219.68% |
Return on Invested Capital (Normalized) | −69.40% |
Return on Assets
EDSA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Lhnzzkts | Ptzmvb | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nrzzlvwrv | Bjnpmm | $65B | |||
| argenx SE ADR
ARGX
| Knfgnxkgg | Yftv | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zylyzcvys | Jgbhfjz | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Znstftpt | Tknktkf | $25B | |||
| BioNTech SE ADR
BNTX
| Sjnkdtxmn | Cdnw | $22B | |||
| Incyte Corp
INCY
| Fpzljcchh | Rvxwq | $21B | |||
| Moderna Inc
MRNA
| Kmvpdswhm | Rgtp | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Hmdzylnf | Ntm | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Ggyvbgrmk | Nfmjp | $13B |
United States